|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Castillo LF, Tascón R, Huvelle MR Lago,
Novack G, Llorens MC, Dos Santos AF, Shortrede J, Cabanillas AM,
Bal de Kier Joffé E, Labriola L, et al: Glypican-3 induces a
mesenchymal to epithelial transition in human breast cancer cells.
Oncotarget. 7:60133–60154. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lorusso G and Rüegg C: New insights into
the mechanisms of organ-specific breast cancer metastasis. Semin
Cancer Biol. 22:226–233. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Li T, Zhang C, Ding Y, Zhai W, Liu K, Bu
F, Tu T, Sun L, Zhu W, Zhou F, et al: Umbilical cord-derived
mesenchymal stem cells promote proliferation and migration in MCF-7
and MDA-MB-231 breast cancer cells through activation of the ERK
pathway. Oncol Rep. 34:1469–1477. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Neuzillet C, Tijeras-Raballand A, de
Mestier L, Cros J, Faivre S and Raymond E: MEK in cancer and cancer
therapy. Pharmacol Ther. 141:160–171. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Heigener DF, Gandara DR and Reck M:
Targeting of MEK in lung cancer therapeutics. Lancet Respir Med.
3:319–327. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Templeton IE and Musib L: MEK inhibitors
beyond monotherapy: Current and future development. Curr Opin
Pharmacol. 23:61–67. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Britten CD: PI3K and MEK inhibitor
combinations: Examining the evidence in selected tumor types.
Cancer Chemother Pharmacol. 71:1395–1409. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Downward J: Targeting RAS signalling
pathways in cancer therapy. Nat Rev Cancer. 3:11–22. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gu Y, Helenius M, Väänänen K, Bulanova D,
Saarela J, Sokolenko A, Martens J, Imyanitov E and Kuznetsov S:
BRCA1-deficient breast cancer cell lines are resistant to MEK
inhibitors and show distinct sensitivities to 6-thioguanine. Sci
Rep. 6:282172016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mirzoeva OK, Das D, Heiser LM,
Bhattacharya S, Siwak D, Gendelman R, Bayani N, Wang NJ, Neve RM,
Guan Y, et al: Basal subtype and MAPK/ERK kinase
(MEK)-phosphoinositide 3-kinase feedback signaling determine
susceptibility of breast cancer cells to MEK inhibition. Cancer
Res. 69:565–572. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Maiello MR, D'Alessio A, Bevilacqua S,
Gallo M, Normanno N and De Luca A: EGFR and MEK blockade in triple
negative breast cancer cells. J Cell Biochem. 116:2778–2785. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ji H, Lee JH, Wang Y, Pang Y, Zhang T, Xia
Y, Zhong L, Lyu J and Lu Z: EGFR phosphorylates FAM129B to promote
Ras activation. Proc Natl Acad Sci USA. 113:pp. 644–649. 2016;
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jung YS, Jun S, Lee SH, Sharma A and Park
JI: Wnt2 complements Wnt/β-catenin signaling in colorectal cancer.
Oncotarget. 6:37257–37268. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sano M, Driscoll DR, DeJesus-Monge WE,
Quattrochi B, Appleman VA, Ou J, Zhu LJ, Yoshida N, Yamazaki S,
Takayama T, et al: Activation of WNT/β-catenin signaling enhances
pancreatic cancer development and the malignant potential via
up-regulation of Cyr61. Neoplasia. 18:785–794. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wickström M, Dyberg C, Milosevic J, Einvik
C, Calero R, Sveinbjörnsson B, Sandén E, Darabi A, Siesjö P, Kool
M, et al: Wnt/β-catenin pathway regulates MGMT gene expression in
cancer and inhibition of Wnt signalling prevents chemoresistance.
Nat Commun. 6:89042015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang X, Zhu J, Li Y, Lin T, Siclari VA,
Chandra A, Candela EM, Koyama E, Enomoto-Iwamoto M and Qin L:
Epidermal growth factor receptor (EGFR) signaling regulates
epiphyseal cartilage development through β-catenin-dependent and
-independent pathways. J Biol Chem. 288:32229–32240. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tzeng HE, Yang L, Chen K, Wang Y, Liu YR,
Pan SL, Gaur S, Hu S and Yen Y: The pan-PI3K inhibitor GDC-0941
activates canonical WNT signaling to confer resistance in TNBC
cells: Resistance reversal with WNT inhibitor. Oncotarget.
6:11061–11073. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
De P, Carlson JH, Wu H, Marcus A,
Leyland-Jones B and Dey N: Wnt-beta-catenin pathway signals
metastasis-associated tumor cell phenotypes in triple negative
breast cancers. Oncotarget. 7:43124–43149. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Timmermans-Sprang EP, Gracanin A and Mol
JA: High basal Wnt signaling is further induced by PI3K/mTor
inhibition but sensitive to cSRC inhibition in mammary carcinoma
cell lines with HER2/3 overexpression. BMC Cancer. 15:5452015.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen L, Kang QH, Chen Y, Zhang YH, Li Q,
Xie SQ and Wang CJ: Distinct roles of Akt1 in regulating
proliferation, migration and invasion in HepG2 and HCT 116 cells.
Oncol Rep. 31:737–744. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zheng XH, Nie X, Liu HY, Fang YM, Zhao Y
and Xia LX: TMPyP4 promotes cancer cell migration at low doses, but
induces cell death at high doses. Sci Rep. 6:265922016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liao L, Song M, Li X, Tang L, Zhang T,
Zhang L, Pan Y, Chouchane L and Ma X: E3 ubiquitin ligase UBR5
drives the growth and metastasis of triple-negative breast cancer.
Cancer Res. 77:2090–2101. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Toulany M, Iida M, Keinath S, Iyi FF,
Mueck K, Fehrenbacher B, Mansour WY, Schaller M, Wheeler DL and
Rodemann HP: Dual targeting of PI3K and MEK enhances the radiation
response of K-RAS mutated non-small cell lung cancer. Oncotarget.
7:43746–43761. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ren W, Liu Y, Wan S, Fei C, Wang W, Chen
Y, Zhang Z, Wang T, Wang J, Zhou L, et al: BMP9 inhibits
proliferation and metastasis of HER2-positive SK-BR-3 breast cancer
cells through ERK1/2 and PI3K/AKT pathways. PLoS One. 9:e968162014.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ma L, Wang X, Jia T, Wei W, Chua MS and So
S: Tankyrase inhibitors attenuate WNT/β-catenin signaling and
inhibit growth of hepatocellular carcinoma cells. Oncotarget.
6:25390–25401. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Huang SM, Mishina YM, Liu S, Cheung A,
Stegmeier F, Michaud GA, Charlat O, Wiellette E, Zhang Y, Wiessner
S, et al: Tankyrase inhibition stabilizes axin and antagonizes Wnt
signalling. Nature. 461:614–620. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yang W, Xia Y, Ji H, Zheng Y, Liang J,
Huang W, Gao X, Aldape K and Lu Z: Nuclear PKM2 regulates β-catenin
transactivation upon EGFR activation. Nature. 480:118–122. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lee CH, Hung HW, Hung PH and Shieh YS:
Epidermal growth factor receptor regulates beta-catenin location,
stability, and transcriptional activity in oral cancer. Mol Cancer.
9:642010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tanaka R, Tomosugi M, Sakai T and Sowa Y:
MEK inhibitor suppresses expression of the miR-17-92 cluster with
G1 phase arrest in HT-29 human colon cancer cells and
MIA PaCa-2 pancreatic cancer cells. Anticancer Res. 36:4537–4543.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tanaka T, Higashi M, Kimura K, Wakao J,
Fumino S, Iehara T, Hosoi H, Sakai T and Tajiri T: MEK inhibitors
as a novel therapy for neuroblastoma: Their in vitro effects and
predicting their efficacy. J Pediatr Surg. 51:2074–2079. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang Y, Nie H, Zhao X, Qin Y and Gong X:
Bicyclol induces cell cycle arrest and autophagy in HepG2 human
hepatocellular carcinoma cells through the PI3K/AKT and
Ras/Raf/MEK/ERK pathways. BMC Cancer. 16:7422016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhou Y, Hu HY, Meng W, Jiang L, Zhang X,
Sha JJ, Lu Z and Yao Y: MEK inhibitor effective against
proliferation in breast cancer cell. Tumour Biol. 35:9269–9279.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ye J, Li A, Liu Q, Wang X and Zhou J:
Inhibition of mitogen-activated protein kinase kinase enhances
apoptosis induced by arsenic trioxide in human breast cancer MCF-7
cells. Clin Exp Pharmacol Physiol. 32:1042–1048. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tan Z, Zheng H, Liu X, Zhang W, Zhu J, Wu
G, Cao L, Song J, Wu S, Song L, et al: MicroRNA-1229 overexpression
promotes cell proliferation and tumorigenicity and activates
Wnt/β-catenin signaling in breast cancer. Oncotarget.
7:24076–24087. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Jiang Q, He M, Guan S, Ma M, Wu H, Yu Z,
Jiang L, Wang Y, Zong X, Jin F, et al: MicroRNA-100 suppresses the
migration and invasion of breast cancer cells by targeting FZD-8
and inhibiting Wnt/β-catenin signaling pathway. Tumour Biol.
37:5001–5011. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
McCubrey JA, Steelman LS, Chappell WH,
Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M,
Tafuri A, et al: Roles of the Raf/MEK/ERK pathway in cell growth,
malignant transformation and drug resistance. Biochim Biophys Acta.
1773:1263–1284. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Galante JM, Mortenson MM, Bowles TL,
Virudachalam S and Bold RJ: ERK/BCL-2 pathway in the resistance of
pancreatic cancer to anoikis. J Surg Res. 152:18–25. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kobayashi M, Funayama R, Ohnuma S, Unno M
and Nakayama K: Wnt-β-catenin signaling regulates ABCC3 (MRP3)
transporter expression in colorectal cancer. Cancer Sci.
107:1776–1784. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lin D, Kuang G, Wan J, Zhang X and Li H,
Gong X and Li H: Luteolin suppresses the metastasis of
triple-negative breast cancer by reversing
epithelial-to-mesenchymal transition via downregulation of
β-catenin expression. Oncol Rep. 37:895–902. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Gu JJ, Rouse C, Xu X, Wang J, Onaitis MW
and Pendergast AM: Inactivation of ABL kinases suppresses non-small
cell lung cancer metastasis. JCI Insight. 1:e896472016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Paul I, Bhattacharya S, Chatterjee A and
Ghosh MK: Current understanding on EGFR and Wnt/β-catenin signaling
in glioma and their possible crosstalk. Genes Cancer. 4:427–446.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Meng X, Hu B, Hossain MM, Chen G, Sun Y
and Zhang X: ADAM17-siRNA inhibits MCF-7 breast cancer through
EGFR-PI3K-AKT activation. Int J Oncol. 49:682–690. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Li RH, Huang WH, Wu JD, Du CW and Zhang
GJ: EGFR expression is associated with cytoplasmic staining of
CXCR4 and predicts poor prognosis in triple-negative breast
carcinomas. Oncol Lett. 13:695–703. 2017.PubMed/NCBI
|
|
45
|
Gao C, Chen G, Romero G, Moschos S, Xu X
and Hu J: Induction of Gsk3β-β-TrCP interaction is required for
late phase stabilization of β-catenin in canonical Wnt signaling. J
Biol Chem. 289:7099–7108. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Gong F, Wang G, Ye J, Li T, Bai H and Wang
W: 14-3-3β regulates the proliferation of glioma cells through the
GSK3β/β-catenin signaling pathway. Oncol Rep. 30:2976–2982. 2013.
View Article : Google Scholar : PubMed/NCBI
|
